Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Novel treatments for systemic lupus erythematosus
Mary Gayed
, Caroline Gordon
Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Article
23
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel treatments for systemic lupus erythematosus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Novel Treatments
100%
Systemic Lupus Erythematosus
100%
B-lymphocyte Stimulator (BLyS)
66%
B Cells
33%
Autoantibodies
33%
Cyclophosphamide
33%
Merck
16%
CD28
16%
CD40 Ligand (CD40L)
16%
CD40
16%
Costimulatory Molecules
16%
Soluble Factors
16%
Cytokine Pathways
16%
Autoimmune Disease
16%
IgG1
16%
Methotrexate
16%
New Drugs
16%
Fusion Protein
16%
Corticosteroids
16%
Autoimmunity
16%
Lupus Nephritis
16%
Immunosuppressive Drugs
16%
Mycophenolate Mofetil
16%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
16%
Therapeutic Strategies
16%
Stimulatory Effect
16%
Transmembrane
16%
Phase III Clinical Trial
16%
Ligand Interaction
16%
Human Genome
16%
Anti-CD20 Antibody
16%
Promising Strategies
16%
Hydroxychloroquine
16%
Cell Stimulation
16%
Patient-specific Therapy
16%
Calcium Signal Modulator
16%
CD22
16%
Abatacept
16%
Molecule Interaction
16%
Inducing Ligand
16%
GlaxoSmithKline
16%
Belimumab
16%
Atacicept
16%
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
B Cell
33%
Autoantibodies
33%
Cyclophosphamide
33%
Clinical Trial
16%
Cytokine
16%
Methotrexate
16%
CD40 Ligand
16%
Immunoglobulin G1
16%
Autoimmune Disease
16%
Immunoglobulin
16%
Lupus Nephritis
16%
Mycophenolate Mofetil
16%
Immunosuppressive Drug
16%
Isotopes of Calcium
16%
Azathioprine
16%
Human Genome
16%
CD20 Antibody
16%
Autoimmunity
16%
Alternative Complement Pathway C3 C5 Convertase
16%
Hydroxychloroquine
16%
CTLA-4
16%
Chimeric Protein
16%
Abatacept
16%
Atacicept
16%
Abetimus
16%
B-Cell Activating Factor
16%
Belimumab
16%
Diseases
16%
Immunology and Microbiology
Systemic Lupus Erythematosus
100%
B Cell
33%
Autoantibodies
33%
Cyclophosphamide
33%
CD28
16%
Cytokine
16%
CD40 Ligand
16%
Intravenous Immunoglobulin
16%
Nephritis
16%
Autoimmune Disease
16%
Immunoglobulin G1
16%
Autoimmunity
16%
Lupus Erythematosus
16%
CTLA-4
16%
Immunosuppressive Drug
16%
Cell Stimulation
16%
Methotrexate
16%
B Cell Activating Factor
16%
Azathioprine
16%
Mycophenolate Mofetil
16%
Complement Factor B
16%
CD20 Antibody
16%
Human Genome
16%
CD22
16%
Hydroxychloroquine
16%
Belimumab
16%
Abatacept
16%
Atacicept
16%
Abetimus
16%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Autoantibodies
33%
Cyclophosphamide
33%
Immunoglobulin
16%
CD40 Ligand
16%
Clinical Trial
16%
Cytokine
16%
Methotrexate
16%
Immunoglobulin G1
16%
Autoimmune Disease
16%
Immunosuppressive Agent
16%
Lupus Erythematosus Nephritis
16%
Mycophenolate Mofetil
16%
Cytotoxic T Lymphocyte Antigen 4
16%
Chimeric Protein
16%
Alternative Complement Pathway C3 C5 Convertase
16%
Azathioprine
16%
Hydroxychloroquine
16%
Abatacept
16%
Belimumab
16%
CD20 Antibody
16%
Atacicept
16%
Abetimus
16%
B Cell Activating Factor
16%
Diseases
16%